Literature DB >> 20111633

Focal therapy: a new paradigm for the treatment of prostate cancer.

Basir Tareen, Guilherme Godoy, Samir S Taneja.   

Abstract

Focal therapy has been proposed in recent years as a means of bridging the gap between radical prostatectomy and active surveillance for treatment of prostate cancer. The rationale for focal therapy comes from its success in treating other malignancies. One of the challenges in applying such an approach to the treatment of prostate cancer has been the multifocal nature of the disease. This review addresses the selection of potentially ideal candidates for focal therapy and discusses which modalities are currently being used and proposed for focal therapy. Setting and meeting guidelines for oncologic efficacy is a challenge we must embrace to safely deliver this potentially revolutionary approach to treating men with prostate cancer.

Entities:  

Keywords:  Cryosurgery; Focal therapy; Photodynamic therapy; Prostate-specific antigen; Prostatectomy; Prostatic neoplasms; Ultrasound, high-intensity focused, transrectal

Year:  2009        PMID： 20111633      PMCID： PMC2809988     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


  54 in total

1.  Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal--pelvic phased-array coils.

Authors:  H Hricak; S White; D Vigneron; J Kurhanewicz; A Kosco; D Levin; J Weiss; P Narayan; P R Carroll
Journal:  Radiology       Date:  1994-12       Impact factor: 11.105

2.  Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy.

Authors:  Anurag K Singh; Jochen Kruecker; Sheng Xu; Neil Glossop; Peter Guion; Karen Ullman; Peter L Choyke; Bradford J Wood
Journal:  BJU Int       Date:  2007-12-05       Impact factor: 5.588

3.  Patient selection determines the prostate cancer yield of dynamic contrast-enhanced magnetic resonance imaging-guided transrectal biopsies in a closed 3-Tesla scanner.

Authors:  Anurag K Singh; Axel Krieger; Jean-Baptiste Lattouf; Peter Guion; Robert L Grubb; Paul S Albert; Greg Metzger; Karen Ullman; Sharon Smith; Gabor Fichtinger; Iclal Ocak; Peter Choyke; Cynthia Ménard; Jonathan Coleman
Journal:  BJU Int       Date:  2007-10-08       Impact factor: 5.588

4.  Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy.

Authors:  Bradley C Leibovich; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

5.  Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy.

Authors:  W J Catalona; J W Basler
Journal:  J Urol       Date:  1993-09       Impact factor: 7.450

6.  Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort.

Authors:  Basir Tareen; Alex Sankin; Guilherme Godoy; Steve Temkin; Herbert Lepor; Samir S Taneja
Journal:  Urology       Date:  2008-11-26       Impact factor: 2.649

7.  Pathological characteristics of prostate cancer detected through prostate specific antigen based screening.

Authors:  Stacy Loeb; Chris M Gonzalez; Kimberly A Roehl; Misop Han; Jo Ann V Antenor; Ronald L Yap; William J Catalona
Journal:  J Urol       Date:  2006-03       Impact factor: 7.450

8.  Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results.

Authors:  David S Ellis; Theodore B Manny; John C Rewcastle
Journal:  Urology       Date:  2007-12       Impact factor: 2.649

9.  Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy.

Authors:  Gary Onik; Winston Barzell
Journal:  Urol Oncol       Date:  2008 Sep-Oct       Impact factor: 3.498

Review 10.  Focal or subtotal therapy for early stage prostate cancer.

Authors:  J Stephen Jones
Journal:  Curr Treat Options Oncol       Date:  2007-06
View more
  10 in total

1.  Imaging of prostate cancer: a platform for 3D co-registration of in-vivo MRI ex-vivo MRI and pathology.

Authors:  Clement Orczyk; Artem Mikheev; Andrew B Rosenkrantz; Jonathan Melamed; Samir S Taneja; Henry Rusinek
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2012-02-23

2.  Ganoderic Acid DM: An Alternative Agent for the Treatment of Advanced Prostate Cancer.

Authors:  Benjamin M Johnson; Bently P Doonan; Faisal F Radwan; Azizul Haque
Journal:  Open Prost Cancer J       Date:  2010-01-01

3.  Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost.

Authors:  Michael Pinkawa; Richard Holy; Marc D Piroth; Jens Klotz; Sandra Nussen; Thomas Krohn; Felix M Mottaghy; Martin Weibrecht; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2010-09-30       Impact factor: 3.621

Review 4.  An update on focal therapy for prostate cancer.

Authors:  Marlon Perera; Nishanth Krishnananthan; Uri Lindner; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2016-09-27       Impact factor: 14.432

Review 5.  The prostate cancer focal therapy.

Authors:  Filippo Pesapane; Francesca Patella; Enrico Maria Fumarola; Edoardo Zanchetta; Chiara Floridi; Gianpaolo Carrafiello; Chloë Standaert
Journal:  Gland Surg       Date:  2018-04

6.  Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells.

Authors:  Benjamin M Johnson; Faisal F Y Radwan; Azim Hossain; Bently P Doonan; Jessica D Hathaway-Schrader; Jason M God; Christina V Voelkel-Johnson; Narendra L Banik; Sakamuri V Reddy; Azizul Haque
Journal:  J Cell Biochem       Date:  2018-10-30       Impact factor: 4.429

7.  Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy.

Authors:  Jeffrey Vainshtein; Eyad Abu-Isa; Karin B Olson; Michael E Ray; Howard M Sandler; Dan Normolle; Dale W Litzenberg; Kathryn Masi; Charlie Pan; Daniel A Hamstra
Journal:  Radiat Oncol       Date:  2012-06-09       Impact factor: 3.481

8.  Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.

Authors:  Colin S Cooper; Rosalind Eeles; David C Wedge; Peter Van Loo; Anne Y Warren; Christopher S Foster; Hayley C Whitaker; Ultan McDermott; Daniel S Brewer; David E Neal; Gunes Gundem; Ludmil B Alexandrov; Barbara Kremeyer; Adam Butler; Andrew G Lynch; Niedzica Camacho; Charlie E Massie; Jonathan Kay; Hayley J Luxton; Sandra Edwards; ZSofia Kote-Jarai; Nening Dennis; Sue Merson; Daniel Leongamornlert; Jorge Zamora; Cathy Corbishley; Sarah Thomas; Serena Nik-Zainal; Sarah O'Meara; Lucy Matthews; Jeremy Clark; Rachel Hurst; Richard Mithen; Robert G Bristow; Paul C Boutros; Michael Fraser; Susanna Cooke; Keiran Raine; David Jones; Andrew Menzies; Lucy Stebbings; Jon Hinton; Jon Teague; Stuart McLaren; Laura Mudie; Claire Hardy; Elizabeth Anderson; Olivia Joseph; Victoria Goody; Ben Robinson; Mark Maddison; Stephen Gamble; Christopher Greenman; Dan Berney; Steven Hazell; Naomi Livni; Cyril Fisher; Christopher Ogden; Pardeep Kumar; Alan Thompson; Christopher Woodhouse; David Nicol; Erik Mayer; Tim Dudderidge; Nimish C Shah; Vincent Gnanapragasam; Thierry Voet; Peter Campbell; Andrew Futreal; Douglas Easton; Michael R Stratton
Journal:  Nat Genet       Date:  2015-03-02       Impact factor: 38.330

9.  Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors.

Authors:  Ethel J Ngen; Ying Chen; Babak Behnam Azad; Srikanth Boinapally; Desmond Jacob; Ala Lisok; Chentian Shen; Mir S Hossain; Jiefu Jin; Zaver M Bhujwalla; Martin G Pomper; Sangeeta R Banerjee
Journal:  Nanotheranostics       Date:  2021-01-19

Review 10.  Low temperature plasma: a novel focal therapy for localized prostate cancer?

Authors:  Adam M Hirst; Fiona M Frame; Norman J Maitland; Deborah O'Connell
Journal:  Biomed Res Int       Date:  2014-03-13       Impact factor: 3.411
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.